Lunaphore, a Lausanne, Switzerland-based life sciences company, raised CHF40M in its first close of Series D funding.
The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB) with participation from PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine. The funding includes a EUR 10M venture debt facility provided by Norgine Ventures.
The company intends to use the funds to strengthen its portfolio offering in spatial biology as well as support commercial execution to address demand from customers.
Led by CEO Ata Tuna Ciftlik, Lunaphore Technologies provides solutions based on chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology to empower researchers in immunology, immuno-oncology, and neuroscience to advance scientific discovery and drug development. The technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes.
FinSMEs
24/03/2023